Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PANZYGA safely and effectively. See full prescribing information for PANZYGA. PANZYGA, (immune globulin intravenous, human - ifas) 10% Liquid Preparation Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-other
PANZYGA is indicated for treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. PANZYGA is indicated for the treatment of adult patients with ITP to raise platelet counts to control or prevent bleeding. PANZYGA is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
- generic_name
- immune globulin intravenous (human)
- product_names
- immune globulin intravenous (human)
- ndc
- 0069-1011, 0069-1011-01, 0069-1011-02, 0069-1109, 0069-1109-01, 0069-1109-02, 0069-1224, 0069-1224-01, 0069-1224-02, 0069-1312, 0069-1312-01, 0069-1312-02, 0069-1415, 0069-1415-01, 0069-1415-02, 0069-1558, 0069-1558-01, 0069-1558-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en